Posts by
Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology
Access will enable GSK to...
Hamburg, Germany, and Toronto, Canada, 17 October, 2022:Evotec SE (Frankfurt Stock...
Agreement key to building pan-European market access practice while underscoring a think global, act local commitment
$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development
Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients
Acquisition adds breakthrough calcitonin gene-related peptide portfolio, including NURTEC® ODT, to address needs of millions of migraine patients worldwide
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 3, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States.
London, 28 September 2022 — Novartis Pharmaceuticals UK has today announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.
Modern name, purpose, and visual identity mark inspiring next chapter for maker of iconic, trusted brands, including Tylenol, Neutrogena, Listerine, and Band-Aid Brand
Bern, Switzerland, and Boston, USA September 28, 2022 – RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical companies and its partnership with Heidelberg Engineering to distribute RetinAI’s Disease AI Apps for research use in the U.S. The Boston office will be RetinAI’s second location, in addition to its Bern headquarters.
